This lecture examines the management and safety profile of Disease-Modifying Antirheumatic Drugs (DMARDs) in patients with rheumatoid arthritis and autoimmune diseases who are planning for pregnancy, currently pregnant, or lactating. It covers risk stratification, drug continuation vs. discontinuation strategies (e.g., stopping methotrexate prior to conception, continuing hydroxychloroquine or sulfasalazine), and evidence-based clinical guidelines for balancing maternal disease control with fetal and neonatal safety.
